Amneal Pharmaceuticals Q3 Revenue $863M; Raises 2026 Guidance
Amneal Pharmaceuticals announced its third quarter 2026 financial results, reporting a 10% increase in net revenue to $863 million and a 30% rise in Adjusted EBITDA to $207 million. The company also saw a 53% increase in Adjusted Diluted EPS to $0.26. Despite a GAAP net loss of $22 million, driven by acquisition and integration costs, Amneal is increasing its full-year 2026 guidance for net revenue, Adjusted EBITDA, and Adjusted Diluted EPS. The company highlighted strong performance across its segments, successful integration of Kashiv, and upcoming product launches.
Key Highlights
- Amneal Pharmaceuticals Q3 2026 Net Revenue $863M, up 10% YoY.
- Q3 2026 GAAP Net Loss $(22M) vs. Net Income $2M in Q3 2025.
- Q3 2026 Adjusted EBITDA $207M, up 30% YoY.
- Q3 2026 Adjusted Diluted EPS $0.26, up 53% YoY.
- Updating 2026 Full Year Guidance: Net Revenue $3.15B-$3.25B, Adjusted EBITDA $800M-$815M.
- Company hosts conference call and webcast on November 3, 2026, at 8:30 am ET.
- Kashiv integration proceeding well; new launches include biosimilars, lanreotide, CREXONT®, BREKIYA® autoinjector.
Price Impact
More from AMRX
Amneal Pharmaceuticals Acquires Kashiv BioSciences for $1.3B; Q3 Revenue $863M, Net Loss $(21.7)M
Amneal Completes Kashiv BioSciences Acquisition for $375M Cash
Amneal Q2 Net Revenue $796.2M, Net Income $57.7M; New Deals Signed